(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/212899 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61K 47/26* (2006.01)
A61K 47/18 (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2022/023141

(22) International Filing Date:
01 April 2022 (01.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/170,446	03 April 2021 (03.04.2021)	US
63/194,929	28 May 2021 (28.05.2021)	US
63/210,481	14 June 2021 (14.06.2021)	US
63/257,999	20 October 2021 (20.10.2021)	US
63/299,879	14 January 2022 (14.01.2022)	US

(71) Applicant: **AMBRX, INC.** [US/US]; 10975 North Torrey Pines Road, La Jolla, California 92037 (US).

(72) Inventors: **TIAN, Feng**; c/o Ambrx, Inc., 10975 North Torrey Pines Road, La Jolla, California 92037 (US). **YAO, Sulan**; c/o Ambrx, Inc., 10975 North Torrey Pines Road, La Jolla, California 92037 (US). **YAN, Jinchun**; c/o Ambrx, Inc., 10975 North Torrey Pines Road, La Jolla, California 92037 (US). **XIA, Gang**; c/o Ambrx, Inc., 10975 North Torrey Pines Road, La Jolla, California 92037 (US). **JI, Yanping**; c/o Ambrx, Inc., 10975 North Torrey Pines Road, La Jolla, California 92037 (US). **XIONG, Gaozhun**; c/o Ambrx, Inc., 10975 North Torrey Pines Road, La Jolla, California 92037 (US). **LIANG, Xuejun**; c/o Ambrx, Inc., 10975 North Torrey Pines Road, La Jolla, California 92037 (US).

(74) Agent: **TIAN, Feng**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

WO 2022/212899 A1

(54) Title: ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF




FIG. 1

(57) Abstract: Disclosed herein are antibody-drug conjugates (ADCs) whose antibodies include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The ADCs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid ADCs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such ADCs. Typically, the modified ADCs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid ADCs and modified non-natural amino acid ADCs, including therapeutic, diagnostic, and other biotechnology use.

[Continued on next page]

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*